ORGANOGENESIS HOLDINGS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $2.25 per share for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-05-07
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $2.25, a 19.05% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $1.89, a 0.00% change year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $1.89, a 43.18% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $1.32, a 66.50% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $1.92, a 1.59% increase from fiscal 2024.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $1.89, a 43.18% increase from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $1.32, a 66.50% decline from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $3.94, a 25.94% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-03-31 | $2.25 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $1.92 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $1.89 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $1.89 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $1.89 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $1.89 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $1.89 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $1.89 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $1.89 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $1.32 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $1.32 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $1.32 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | $1.32 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | $3.94 10-K · filed 2024-02-29 | |||
| 2022-09-30 | $3.94 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $3.94 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | $3.94 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $5.32 10-K · filed 2023-03-01 | |||
| 2021-09-30 | $5.32 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | $5.31 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | $5.31 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $1.05 10-K · filed 2022-03-01 | |||
| 2020-09-30 | $1.05 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $1.04 10-Q · filed 2021-08-09 | |||
| 2019-12-31 | $3.24 10-K · filed 2021-03-16 | |||
| 2019-09-30 | $3.24 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | $3.24 10-Q · filed 2019-08-09 | |||
| 2019-03-31 | $2.39 10-Q · filed 2019-05-10 | |||
| 2018-12-31 | $2.39 10-K · filed 2020-03-09 | |||
| 2018-09-30 | $2.39 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | $2.39 10-Q · filed 2019-08-09 | |||
| 2017-12-31 | $1.62 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |